Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the aa-galactosidase A (GLA) gene

Gervas-Arruga, J. ; Cebolla, J.J. ; Irun, P. ; Perez-Lopez, J. ; Plaza, L. ; Roche, J.C. ; Capablo, J.L. ; Rodriguez-Rey, J. ; Pocovi, M. (Universidad de Zaragoza) ; Giraldo, P.

Resumen: Background: Accumulation of galactosphingolipids is a general characteristic of Fabry disease, a lysosomal storage disorder caused by the deficient activity of a-galactosidase A encoded by the GLA gene. Although many polymorphic GLA haplotypes have been described, it is still unclear whether some of these variants are causative of disease symptoms. We report the study of an inheritance of a complex intronic haplotype (CIH) (c.-10C > T, c.369 + 990C > A, c.370-81_370-77delCAGCC, c.640-16A > G, c.1000-22C > T) within the GLA gene associated with Fabry-like symptoms and galactosphingolipid accumulation.
We analysed a-Gal A activity in plasma, leukocytes and skin fibroblasts in patients, and measured accumulation of galactosphingolipids by enzymatic methods and immunofluorescence techniques. Additionally, we evaluated GLA expression using quantitative PCR, EMSA, and cDNA cloning.
Results: CIH carriers had an altered GLA expression pattern, although most of the carriers had high residual enzyme activity in plasma, leukocytes and in skin fibroblasts. Nonetheless, CIH carriers had significant galactosphingolipid accumulation in fibroblasts in comparison with controls, and also glycolipid deposits in renal tubules and glomeruli. EMSA assays indicated that the c.-10C > T variant in the promoter affected a nuclear protein binding site.
Conclusions: Thus, inheritance of the CIH caused an mRNA deregulation altering the GLA expression pattern, producing a tissue glycolipid storage.

Idioma: Inglés

DOI: 10.1186/s12863-015-0267-z

Año: 2015

Publicado en: BMC GENETICS 16, 109 (2015), [13 pp.]
ISSN: 1471-2156

Factor impacto JCR: 2.152 (2015)

Categ. JCR: GENETICS & HEREDITY rank: 100 / 166 = 0.602 (2015) - Q3 - T2

Factor impacto SCIMAGO: 1.176 - Genetics (clinical) (Q2) - Genetics (Q2)

Financiación: info:eu-repo/grantAgreement/ES/FIS/FIS09-02556

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)